GlassScriptPhysician profile
Brian D Clarke
NPI 1316960669
$17,719.08
in general payments reported to CMS, 2019-2025
39 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,891 · 2020: $1,655 · 2021: $2,319 · 2022: $2,097 · 2023: $3,219 · 2024: $3,312 · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,511 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,511.01 |
| Education | $246.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,559.83 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,303.84 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,989.75 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,195.74 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $1,128.64 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $960.42 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $841.02 | 2021-2024 | Zeposia |
| Celgene Corporation | $809.02 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $652.72 | 2019-2025 | Suflave, Sutab |
| Gilead Sciences, INC. | $631.68 | 2019-2024 | |
| Ardelyx, INC. | $454.26 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $382.12 | 2021-2023 | |
| Redhill Biopharma INC. | $312.12 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $256.59 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Celltrion USA INC. | $223.03 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.